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 CURRENTOPINION Transoral incisionless fundoplication: current status
Karim Sami Trad
Purpose of review
Transoral incisionless fundoplication (TIF) performed with the EsophyX device (Redmond, Washington, USA)
is a totally endoscopic procedure with the objectives to mechanically repair a defective gastroesophageal
valve and to reduce small hiatal hernias. The recent publication of randomized controlled trials and long-
term follow-up data offers the opportunity to reevaluate this treatment modality and its role in the
management of patients with chronic gastroesophageal reflux disease (GERD).
Recent findings
Randomized controlled trials have confirmed the ability of TIF to eliminate troublesome GERD symptoms,
heal esophagitis, and improve distal esophageal acid exposure in appropriately selected patient
populations. These studies establish TIF’s superiority to conventional medical therapy, especially in clinical
scenarios where proton-pump inhibitors fail to provide complete symptom relief across the spectrum of
classic and atypical GERD manifestations, including regurgitation and laryngopharyngeal reflux. Long-term
data indicate sustained positive outcomes and durability up to 6 years after procedure. These results were
achieved with a low rate of serious adverse events and usually without introducing troublesome dysphagia,
gas bloat, or flatulence.
Summary
Based on the most recent data, TIF appears to be a valuable treatment alternative for the management of
appropriately selected patients with moderate to severe chronic GERD symptoms.
Keywords
atypical gastroesophageal reflux disease symptoms, EsophyX, gastroesophageal reflux disease,
regurgitation, transoral incisionless fundoplication
INTRODUCTION
The first transoral incisionless fundoplication (TIF)
procedure using the EsophyX device was performed
in 2005. Since then, more than 17 000 procedures
have been completed. The initial European
experience and publications focused on the early
iterations of this procedure (endoluminal fundopli-
cation and TIF 1.0) and led to the 2007 Food and
Drug Administration clearance of the EsophyX
device in the United States [1,2]. During those early
years on the US market, struggling to define its
precise role in the management of gastroesophageal
reflux disease (GERD) patients, the TIF procedure
was met with a lack of enthusiasm from leading
gastroenterological and surgical societies. This
may be explained by the unfair comparison of TIF
to the first generation of GERD endoluminal thera-
pies (e.g., EndoCinch, Enteryx, Gatekeeper, and
Endoscopic Plicator System, NDO Surgical, INC,
Mansfield, Massachusetts, USA), which, with the
exception of the Stretta procedure, are no longer
available because of safety concerns or lack of effec-
tiveness. Further, the absence of long-term data
and randomized controlled trials (RCTs) at that time
resulted in inconsistent coverage by third-party
payers and limited adoption of TIF by physicians.
More recently, however, the TIF procedure
performed with the EsophyX device has emerged
as a viable alternative in the management of GERD
patients with hiatal hernias 2 cm or less. In 2015,







] confirmed its effectiveness and demon-
strated its superiority over proton-pump inhibitors
(PPIs) in selected patient populations with
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incomplete symptomatic response to maximal
medical therapy. Furthermore, long-term studies
from Europe [7
&&
] and the United States [8
&
] have
become available, pointing to sustained outcomes
and durability up to 6 years after procedure.
Concurrently, TIF has withstood the test of time
with a solid safety profile. On the strength of this
high-level clinical evidence from TIF studies, the
American Medical Association assigned a new
Current Procedural Terminology code for ‘transoral
esophagogastric fundoplasty’, clearing the way for
wider coverage and adoption.
The study reviews the most relevant literature
published in the past 18 months, focusing on
the currently performed version of the procedure
(TIF 2.0, Fig. 1) [3
&
] and addressing the critical issues
of effectiveness, durability, safety, patient selection,
and physiology.
EFFECTIVENESS
There are three therapy goals for chronic GERD:
improved symptom control, healing of reflux
esophagitis, and prevention of complications [9].







] provided the highest level of evidence
and most comprehensive data on the ability of
TIF to achieve these goals.
Typical gastroesophageal reflux disease
symptoms
The Randomized EsophyX vs. Sham, Placebo-
Controlled Transoral Fundoplication (RESPECT)
trial [3
&
] specifically evaluated the efficacy of TIF
in eliminating troublesome regurgitation as defined
by the Montreal consensus definition [9]. This
double-blind study was carried out at eight
academic and community centers in the United
States. The patients were randomly assigned either
to the TIF group (TIF and placebo pills) or to the
control group (sham procedure and optimized dose
of omeprazole). In selected patients with a hiatal
hernia 2 cm or less, elimination of troublesome
regurgitation was achieved in 67% of TIF/placebo
patients vs. 45% sham/PPI patients at 6-month
follow-up (P<0.023). Further evidence was found
in the TIF EsophyX vs Medical PPI Open Label
(TEMPO) trial, an RCT with a crossover arm, where
troublesome regurgitation was eliminated in 97 and





]. Although high-dose PPI therapy
provided considerable improvements at 6-month
follow-up in the control (crossover) group, an
additional 67% of nonresponders to PPI therapy
reported elimination of troublesome regurgitation
6 months following TIF. Thus, the ability of TIF
to effectively eliminate regurgitation may have
KEY POINTS
 The TIF procedure performed with the EsophyX device
can be effective in treating regurgitation, heartburn,
and laryngopharyngeal reflux refractory to optimal
doses of PPIs in the appropriate patient population.
 TIF is associated with a low rate of serious
complications, and studies have documented that TIF
seldom results in postfundoplication syndromes, such as
dysphagia, gas bloat, and flatulence.
 Ideal candidates for the TIF procedure are chronic
GERD patients who have only mild to moderate
deterioration of the gastroesophageal junction (absent
or small hiatal hernia 2 cm, Hill grade I or II) and
effective esophageal motility.
FIGURE 1. Transoral incisionless fundoplication creates a
2708 anterior partial fundoplication.
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important clinical implications in the treatment of
this challenging patient population.
Elimination of troublesome heartburn has also
been confirmed in the most recent RCTs. Using
primarily the Reflux Disease Questionnaire (RDQ)
to evaluate symptoms, Hunter et al. [3
&
] reported
that TIF provided better control of heartburn
than sham procedure off medication, and that
median heartburn scores significantly decreased
from 2.6 to 0.5 in the TIF/placebo group 6-month
after procedure. In the TEMPO study, sustained
improvements in heartburn scores were reported






Atypical gastroesophageal reflux disease
symptoms
Historically, patients presenting with atypical GERD
symptoms, such as asthma, chronic cough, hoarse-
ness, or chronic sore throat present a therapeutic
challenge because of their unpredictable and
frequently incomplete response to PPIs. Addition-
ally, diagnosing GERD in patients exhibiting only
extraesophageal manifestations is often challeng-
ing. In this setting, objective evidence, such as
ambulatory pH monitoring (% total time pH<4),
impedance testing (symptom index and symptom
association probability), and endoscopic findings of
erosive esophagitis are required to establish the
diagnosis with more certainty [10]. In the TEMPO
trial, elimination of all troublesome atypical symp-
toms in patients with objective documentation of
GERD was achieved in 62% of patients at 6 months





The incremental response from 62 to 82% was not
surprising; previous studies had already suggested
that atypical symptoms tend to resolve at a slower
pace than typical symptoms after antireflux surgery
[11]. Based on these results, the TIF procedure
appears to be a valuable alternative for well selected
patients with significant atypical symptoms.
A European double-blind RCT (TIF vs. sham) was
conducted in five centers using ‘time to treatment
failure’ as the primary end point at 6 months.
Using a composite outcome measure to evaluate
individual therapeutic interventions, Lundell and
colleagues found that significantly more TIF
patients (59%) remained in clinical remission, com-
pared with patients who underwent sham procedure
(9%), P<0.0001. The authors noted that the level of
scientific proof supporting TIF efficacy and use sur-
passes anything currently available outside the area




Lack of durability and poor long-term outcomes
in the first generation of endoluminal therapies
can largely explain their falling out of favor and
ultimately being pulled off the market. Similar
concerns have been raised in the early experience
with TIF; however, review of the recent long-term
follow-up data offers some reassurance.
In a cohort of patients with documented GERD
treated by a single endoscopist, Testoni and
colleagues [7
&&
] reported that symptomatic improve-
ment, as measured by two GERD-specific quality
of life questionnaires, is stable up to 6 years after
TIF. Additionally, the percentage of patients who
either stopped or halved their PPI therapy at 3-year
follow-up seems nearly unchanged at 6 years (84%).
Surprisingly, in the same study, complete discon-
tinuation of PPIs dropped from 61% of patients
at 6 months to 30% at 6 years, with the sharpest
drop observed between 6 and 12 months after TIF.





which suggest that most TIF failures occur within
the first-year after procedure, underlining the con-
sequences of poor patient selection. Furthermore,
PPI use after an endoscopic procedure can often
be explained by easy access to over-the-counter
medications or patients’ tendency to resume PPI
use without objective documentation of GERD.
Table 1. Mean quality of life scores before transoral incisionless fundoplication and at 6 and 12-month follow-up in patient’s















P value (6 vs.
12 months)
RDQ 2.91 (1.32) 0.35 (0.53) 0.50 (0.73) <0.001 <0.001 0.772
Heartburn RDQ 2.99 (2.55) 0.45 (0.86) 0.63 (1.01) <0.001 <0.001 0.776
GERD-HRQL 26.25 (10.51) 5.23 (7.14) 5.41 (6.80) <0.001 <0.001 0.995
Heartburn GERD-HRQL 17.69 (7.51) 3.74 (5.51) 3.76 (4.50) <0.001 <0.001 >0.999
GERD-HRQL, gastroesophageal reflux disease health-related quality of life; PPI, proton pump inhibitor; RDQ, Reflux Disease Questionnaire; TIF, transoral
incisionless fundoplication.
Esophagus
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These factors suggest that PPI use after an endo-
scopic procedure might be an unreliable measure
of success or failure. In fact, recent studies
have demonstrated that PPIs may represent an
acceptable adjunct to TIF procedures in patients
whose GERD symptoms were uncontrolled on





Resolution of GERD symptoms also appears to
be sustained in long-term follow-up studies. In the
TEMPO trial, elimination of troublesome regurgita-
tion was reported in 91% of patients at 3 years and
resolution of atypical symptoms was supported by
normalization of Reflux Symptom Index score in
87% of patients [abstract accepted for a podium
presentation, the Society of American Gastrointes-
tinal and Endoscopic Surgeon (SAGES) 2016 Annual
Meeting]. Most importantly, resolution of both
typical and atypical symptoms remained stable
between the 1 and 3-year follow-up, indicating
durability of TIF and confirming previously reported
results in the large, prospective, multicenter




Consistently, and across all studies, low compli-













]. A 2013 systematic review of
the published TIF literature found that the major
complication rate was 3.2%, which is comparable
with laparoscopic Nissen fundoplication [13]. In a
database from the manufacturer of the EsophyX
device, serious adverse events occurred in 0.41%
of more than 17 000 TIF patients to date (Fig. 2),
and there have been no reported mortalities
following the procedure. In the RESPECT study,
with the exception of brief postoperative epigastric
pain, complications and adverse effects were no
different between TIF/placebo and sham/PPI groups
[3
&
]. Authors of the TEMPO trial attribute the
absence of any serious adverse events in their study
to the experience of the investigators, each having





]. Although improvements in the
device and technique over the last few years
have made the procedure more operator friendly,
a rigorous, standardized training, and a strict
educational curriculum for any new user is critical
to preserving the safety profile of the TIF.
In addition to a strong safety profile, the very
low incidence of new dysphagia, gas bloat, and
excessive flatulence is perhaps one of the most
attractive features of the TIF procedure. Postfundo-
plication syndromes were found to be virtually non-













fact, preexisting dysphagia, gas bloat, and flatulence
were improved after TIF (92, 79, and 81%, respect-
ively, at 6 months) [4
&
]. Thus, it appears that TIF is
well positioned to fill the ‘therapy gap’ between
medical therapy and more invasive surgical




Appropriate patient selection is critical for achiev-
ing good outcomes with any antireflux procedure.
The presence of typical symptoms and a positive
response to PPI therapy have traditionally been
viewed as predictors of successful outcomes follow-



































FIGURE 2. Serious adverse events after transoral incisionless fundoplication. Serious adverse events occurred in 0.41% of
more than 17 000 patients to date (data provided by EndoGastric Solutions).
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such patients are usually satisfied with continued
medical management, many patients with partial
or minimal response to PPI therapy will seek
alternative treatments. In a prospective study
of 158 patients with inadequate symptom control
despite high-dose PPI therapy, those with typical
symptoms (GERD-HRQL>15) were more likely
to have a successful TIF outcome [15
&
]. For patients
with more severe heartburn (GERD-HRQL score>30
on high-dose PPI therapy), preoperative counseling
is key to setting realistic expectations regarding
the likelihood of requiring adjunct acid suppression




Better TIF outcomes are also more likely if there
is minimal anatomic deterioration of the gastroeso-
phageal junction (GEJ) [7
&&
]. The Hill classification
can be used to grade the endoscopic appearance of
the gastroesophageal flap valve on a scale of I–IV,
with higher values reflecting more severe disruption
of the GEJ. The excellent clinical outcomes achieved




] might be credited
to restricting selection to patients with Hill grades
I and II, while excluding patients with severe
erosive esophagitis (Los Angeles grade C or D). In
contrast, the somewhat lower rates of elimination of
troublesome GERD symptoms observed in the
RESPECT trial [3
&
] can be attributed to the inclusion
of patients with Hill grade III and more advanced
disease.
In a single center, unblinded randomized trial
by Witteman et al. [16
&
], poor patient selection may
have contributed to suboptimal outcomes. Despite
sustained improvement in symptoms and quality
of life scores in the TIF group at 12-month follow-
up, the majority of TIF patients (61%) had resumed
PPI therapy and there was no improvement of
esophageal acid exposure from baseline. It is
important to note that 41% of patients in the
TIF arm of this study had Hill grade III or IV valve
at entry, suggesting a large hiatal hernia. Further-
more, several of these TIF procedures were com-
pleted with as few as seven fasteners, whereas the
most recent studies consistently used more than
20 fasteners on average. Incidentally, the number
of fasteners deployed had previously been ident-
ified by Testoni et al. [7
&&
] as an important predictor
of better outcomes.
Thus, based on the critical analysis of recent
data, ideal candidates for the TIF procedure
are chronic GERD patients with partial but
inadequate symptom control on high-dose PPI
therapy who have only mild to moderate
deterioration of the GEJ (absent or small hiatal




TIF has been shown to achieve normalization of acid





] of patients. The TEMPO randomized trial
suggested that near equivalent rates of pH normal-
ization are achieved when comparing TIF and
maximal PPI therapy (52 vs. 54% of patients at
6-month follow-up) [4
&
], a result in line with a report
indicating that 50% of patients with complete reflux
symptom control on twice daily PPI therapy had
normalized acid exposure [17].
Healing of reflux esophagitis, a primary measure
of success in evaluating GERD therapy, does not
consistently correlate with rates of distal esophageal
pH normalization [18]; this holds true with the TIF
procedure. Healing of esophagitis was achieved in a
majority of patients undergoing TIF across various
studies, including the TIF US registry (75% at
24-month follow-up) [8
&
], the RESPECT, and TEMPO




], well above the
rates of pH normalization noted in these same stud-
ies. In the TEMPO trial, healing of reflux esophagitis
rose from 38% in control patients on high-dose PPIs
alone to 85% 6 months after crossover to TIF,
whereas distal esophageal pH normalization, as
evaluated by 48-h pH Bravo testing, fell from
52 to 33%, respectively at these same points. The
reason underlying this disparity between rates of
healing of esophagitis and rates of normalization
of esophageal acid exposure is not clear. We specu-
late that a significant proportion of patients in this
study may have suffered from nonacid reflux or
experienced excessive proximal extent of reflux
episodes [5
&
], a theory that could be confirmed by
impedance testing in future studies.
Although higher rates of pH normalization may
be achieved with traditional antireflux laparoscopic
surgery, such procedures have been associated with
significant rates of postfundoplication syndromes
such as dysphagia and gas bloat [10], likely side-
effects attributable to supracompetent valves. One
might argue that symptom control and healing of
reflux esophagitis are more clinically relevant goals
of GERD therapy than normalization of distal
esophageal acid exposure. As had been observed
in previous studies evaluating GERD therapies
[17,19,20], recent TIF studies confirm the poor
correlation between post-TIF symptom control





In an attempt to explain the mechanism
of action of TIF, recent physiologic studies point
to a decrease in the number of postprandial
transient lower esophageal sphincter relaxation
episodes and to significant reduction in the disten-
sibility of the GEJ [21
&
]. One of the benefits of TIF
Esophagus
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is the selective reduction of liquid-containing reflux
episodes, whereas gas reflux events remain unaf-
fected, accounting for the ability to vent gas follow-
ing the TIF procedure and avoiding the gas bloat
commonly associated with laparoscopic Nissen
fundoplication.
CONCLUSION
The quality of high-level clinical evidence found
in the recent literature supports the efficacy, safety,
and durability of the TIF procedure performed
with the EsophyX device and justifies its use as a
therapeutic option for well selected patients with
chronic GERD. The value of TIF has been demon-
strated in select cases where PPIs fail to achieve
complete symptomatic control. Ongoing studies
focusing on the durability of TIF and comparing
it to established treatments such as laparoscopic
Nissen fundoplication are likely to further solidify
its position in the armamentarium of antireflux
therapies.
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